ICON Appoints Dr. James Cummings as president of ClinicalRM
10 January 2018 - - Dublin, Ireland-based drug development solutions and services provider ICON plc, (NASDAQ: ICLR) has appointed Dr. James Cummings as president of wholly owned subsidiary ClinicalRM, the company said.
ClinicalRM is a full-service contract research organisation providing clinical trial and functional services to government and commercial customers.
Cummings will work closely with the ClinicalRM board, executive team, and ICON leadership in the continued development of the ClinicalRM organisation.
Cummings has over 20 years' experience within the global health and government research and development industries. He is a vaccine and infectious disease specialist and most recently led the Influenza related program at Novavax, Inc, in his role as VP clinical development and translational medicine.
Cummings is a retired Colonel with the US Army and served as director of the Department of Defence's Global Emerging Infectious Surveillance and Response System and as the director of Translational Medicine and Regulated Activities for the Walter Reed Army Institute of Research (WRAIR).
He is replacing ClinicalRM founder and CEO, Victoria Tifft, who will transition her leadership role throughout Q1 2018 and will move to the ClinicalRM board as a non-executive director in February 2018.
ICON provides drug development solutions and services to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management, and analysis of programmes that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently operates from 97 locations in 38 countries and has approximately 13,100 employees.